Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
84 results about "Mouse Melanoma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Preparation method and application of cold-fever tablet
InactiveCN102973667ARich in active ingredientsReduce dosagePill deliveryRespiratory disorderPueraria mirificaPuerarin
The invention provides a preparation method and an application of a cold-fever tablet. The cold-fever tablet is prepared by using 168 g of isatis roots, 126 g of schizonepeta ears, 126 g of bistort roots, 126 g of pueraria mirifica and 126 g of radix bupleuri as raw material drugs via supercritical extraction and microwave-assisted extraction, so that puerarin content in the tablet is increased greatly. The invention also provides the application of the cold-fever tablet in preparing the drug of inhibiting cell proliferation of mouse melanoma lung metastatic lines B16-F10.
Owner:刘殿华 +1
Applicationof A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments
ActiveCN102218069APotent tumor suppressor activityBroad-spectrum tumor suppressor activityOrganic active ingredientsSteroidsTreatment effectMda mb 231
The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549 and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.
Owner:SHANGHAI AO QI MEDICAL TECH
Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent
InactiveUS20050281898A1Improve immunityHigh activityBiocideAntipyreticAbnormal tissue growthHuman tumor
Disclosed are an anti-tumor agent, beverages and foods using the same and a process for manufacturing the anti-tumor agent. The anti-tumor agent according to the present invention exhibits specific effects on human tumor cells A4573 and mouse melanoma B16 cells in vitro. The anti-tumor agent exhibits various immune activities in addition to immune activity against tumors. Beverages and foods containing said anti-tumor agent can be manufactured as health food or the like.
Owner:OTO +1
Preparation method and use of quercetin amide derivative
InactiveCN103214445AStrong proliferation inhibitory effectOrganic active ingredientsOrganic chemistryHuman gastric carcinomaQuercitrin
The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.
Owner:ZHENGZHOU UNIV
Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent
Owner:オトコーポレーション +1
Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin
InactiveUS20080226571A1Improve toleranceImprove securityCosmetic preparationsBiocideEpoxyUltraviolet
A composition based on labdane-diterpenoids that provides better photo protection against both UV A and UV B radiations in the HaCaT human keratinocyte cell lines is disclosed. The composition comprises 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one alone and in combination with 6β-acetoxy-8,13-epoxy-1α,7β,9α-trihydroxylabd-14-en-11-one and / or 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one. The composition protects the cells of the skin from harmful UV A and UV B rays through synergistic mechanisms with utility as a safe long-term cosmetic solution for preventing UV-induced skin damage and to induce sunless tanning. Additionally, the composition enhances melanogenesis in B16F1 mouse melanoma cells acting as tanning inducers / accelerators both in the presence or absence of sunlight. Elevation of melanogenesis confers additional protection against UV-induced skin damage.
Owner:MAJEED MUHAMMED
Small molecular compound for inhibiting PD-1/PD-L1 and application thereof
ActiveCN108774219AHas antitumor activityOrganic active ingredientsOrganic chemistryHigh-Throughput Screening MethodsFluorescence
The invention discloses application of a compound or a pharmaceutically acceptable salt or ester or a solvate compound in the preparation of a PD-1 / PD-L1 small-molecule inhibitor medicament. Potentially active candidate molecules in the compound library are virtually screened out by computer simulation. By using the homogeneous time-resolved fluorescence technique, high-throughput screening of candidate molecule antagonistic PD-1 / PD-L1 binding is performed, and a compound with good activity is selected to perform mouse melanoma B16-F10 tumor-transplanting experiments. Then, it is confirmed that the compounds screened by the invention have the antitumor activity.
Owner:CHINA PHARM UNIV
Anticancer 4'-nor-anthricin and preparation method thereof
InactiveCN103304574ASimple preparation processThe preparation process is simple and controllableOrganic chemistryAntineoplastic agentsPtru catalystHydrogen pressure
The invention discloses an anticancer 4'-nor-anthricin and a preparation method thereof, and belongs to the field of medicine. The anticancer 4'-nor-anthricin is prepared by the following steps of taking podophyllotoxin as raw material, dissolving the podophyllotoxin in acetic acid in an autoclave, adding a palladium-carbon catalyst, carrying out reaction between the podophyllotoxin and hydrogen at the hydrogen pressure of 1.1-2 and at the temperature of 90-100 DEG C to obtain anthricin, and finally carrying out reaction between the anthricin and hydrogen bromide in an acetic acid solution to obtain the 4'-nor-anthricin. Researches find that the anticancer 4'-nor-anthricin has obvious suppressing and apoptosis inducing functions for the cervical cancer cell Hela and the mice melanoma cell B16; the preparation method of the 4'-nor-anthricin is simple, easy to control, low in cost and high in yield.
Owner:SOUTHWEST JIAOTONG UNIV
Application of ginsenoside Ro in preparation of antitumor drugs
InactiveCN105769889AEnhanced inhibitory effectGood inhibition rateOrganic active ingredientsAntineoplastic agentsTumor WeightWilms' tumor
The invention mainly relates to application of ginsenoside Ro in the preparation of antitumor drugs. Experiments for studying on changes in the size of tumors of a mouse injected with ginsenoside Ro show that early inhibition rate for the growth of tumors in the mouse injected with the ginsenoside Ro is substantially unchanged and the tumors enlarge synchronously with tumors in model group animals; after entering logarithmic growth stage, the ginsenoside Ro has enhanced inhibitory action on the enlargement of the tumors, and the inhibition rate is significantly higher than the tumor growth inhibitory action in slow growth stage; it is proved that the ginsenoside Ro has good inhibitory action on mouse melanoma. According to tests for researching change of tumor weight of the mouse injected with the ginsenoside Ro, the ginsenoside Ro has good inhibitory action on the melanoma and can be prepared into new antitumor drugs.
Owner:JIAN SHENGLIYUAN BIOTECH DEV CO LTD
Application of icariside II in preparation of anti-melanoma medicament
The invention belongs to the field of medicament preparation, relates to new medicinal application of icariside II, and particularly relates to application of icariside II in preparation of an anti-melanoma medicament. The icariside II is adopted for intervention experiments of mouse melanoma cell strains and human melanoma cell strains; by observing the inhibiting condition of the icariside II on cell proliferation, the results show that the icariside II can remarkably inhibit the proliferation of B16, A375 and SK-MEL-2 cells in vitro, obviously promote apoptosis of the cells and increase P53 protein phosphorylation and caspace protein expression; and the icariside II can remarkably inhibit loaded B16 mouse subcutaneous transplant tumor volume. Experiment results prove that the icariside II can effectively inhibit the melanoma. The icariside II can further be used for preparing the anti-melanoma medicament by adding proper pharmaceutically-acceptable carriers.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
A kind of camel velvet transfer protein and its preparation method and application
InactiveCN102286085AGood antifungal activityEnhanced inhibitory effectBiocidePeptide/protein ingredientsLipid formationAntifungal
The invention discloses a peganum harmala lipid transfer protein (PHP) and relates to the preparation and use of new protein with antifungal, anticancer and antivirus activities. The method uses seeds of a peganum harmala plant as raw materials and comprises the following steps: preparing a coarse product, performing cationic exchange chromatographic separation and purifying by using a molecular sieve; and gradually separating and collecting a purified component having antibacterial activity, dialyzing, desalting, freeze-drying and thus, obtaining purified PHP. In the invention, a filter paper disc agar diffusion method is adopted, and researches prove the protein has growth inhibiting effect on five plant pathogenic fungi, namely alternaria alternate, penicillium degitatum, rhizopus stuolonifer, magnaporthe grisea and penicillium italicum. An 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method proves that the protein has inhibiting effect on proliferation of human esophageal carcinoma cell Eca109, human cervical cancer cells HeLa, human stomach cancer cells MGC-7, mouse melanoma cells B16 and the like. The protein can inhibit the activity of human immunodeficiency virus 1 (HIV-1) reverse transcriptase. The protein can be used for developing medicines for resisting agricultural pathogenic fungi, tumors and viruses.
Owner:XINJIANG UNIVERSITY
Mouse models to study cachexia
Embodiments of the invention provide mouse tumor models involving either the B16 mouse melanoma or MXT mouse mammary tumor, untreated or treated with chemotherapy and / or anti-cachectic agents, for the study of tumor-generated or cancer therapy-generated cachexia-inducing signals and mechanisms. Other embodiments of the invention also provide additional models, including pre-treatment of mouse skin with anti-cachectic proteins prior to tumor implantation, for the study of anti-cachectic signals and mechanisms generated by the skin. To reduce or reverse tumor- and chemotherapy-induced cachexia, embodiments of the invention use the human proteins placental alkaline phosphatase, transferrin, α1-antitrypsin preparations or combinations thereof as well as chemically synthesized CCDTHT or N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]-ethanaminium iodide or CCDTHT-like compounds.
Owner:ZOLTAN LAB
Preparation method and application of 3H-1,2-dithiole-3-thioketone compound
InactiveCN102993166AAvoid pollutionPromote generationOrganic active ingredientsOrganic chemistryDisiloxaneVulcanization
The invention relates to the field of medicine synthesis and discloses a preparation method and application of a 3H-1,2-dithiole-3-thioketone compound. According to the preparation method of the 3H-1,2-dithiole-3-thioketone compound shown in a formula I described in the specification, the yield of the 3H-1,2-dithiole-3-thioketone compound is improved, the problem of unsafe operation in the production of hexamethyl disiloxane is solved, the environmental pollution is reduced, the preparation method is simple to operate, a vulcanization accelerator is low in price and easy to obtain, the production cost is reduced, and the preparation method is suitable for batch preparation of the 3H-1,2-dithiole-3-thioketone compound shown in the formula I. Furthermore, the 3H-1,2-dithiole-3-thioketone compound shown in the formula I plays a suppression role in multiplication of a human liver cancer HePg2 cell strain, a human lung cancer A549 tumor cell strain, a mouse melanoma B16 tumor cell strain and a human liver cancer SMMC-7721 tumor cell strain, and can be used for preparing antitumor medicines.
Owner:SUZHOU UNIV
Supernatant cultured by DCIK cell and use thereof
InactiveCN101333515AHave directHas an indirect killing effectPowder deliveryMammal material medical ingredientsAbnormal tissue growthSide effect
The invention relates to supernatant cultivated by DCIK cells and an application thereof. The supernatant and a preparation of freeze-dried powder prepared by frozen, dried and concentrated supernatant have good anti-tumor activity in tumor therapy. The supernatant cultivated by DCIK cells contains a series of mixtures of cytokines with biological activity which directly act on cell lines cultivated in vitro, thereby causing the forms of the cell lines such as mice melanoma B16 and THP-1 etc. to be affected and producing growth inhibition. The anti-tumor in vivo experiment shows that the supernatant cultivated by DCIK cells and the preparation of freeze-dried powder thereof can obviously inhibit the growth of the mouse melanoma B16 inoculated subcutaneously without obvious side effect. The invention fully proves the prospects of application and research of supernatant cultivated by DCIK cells, and paves the new way for the research of anti-tumor drugs.
Owner:SHANGHAI UNIV
Application of quercetin derivative in preparation of antitumor medicine
InactiveCN103239437AStrong proliferation inhibitory effectSmall side effectsOrganic active ingredientsAntineoplastic agentsSide effectQuercetin derivatives
The invention discloses application of a compound (QB) shown in a formula I in preparation of medicines for prevention and / or treatment. The MTT experiment displays that the proliferation inhibition effects of the compound QB on the four tumor cells, such as human esophageal squamous carcinoma cell EC109, the human esophageal squamous carcinoma cell EC9706, the human gastric carcinoma cell SGC7901 and mouse melanoma cell B16-F10, are obviously superior to those of quercetin. The inhibition effect of (IC50=5.201mu g / mL) on the EC109 cells is equivalent to that of fluorouracil 5-FU(IC50=5.426mu g / mL), the toxic or side effect is relatively small, and the compound is a potential antitumor candidate compound.
Owner:ZHENGZHOU UNIV
4-aminopyrrolopyrimidine derivative and preparation method and application thereof
ActiveCN111100130ANovel structureInhibition of activityOrganic active ingredientsOrganic chemistryDiseaseStage melanoma
The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The compound can significantly inhibit the activity of RIPK1 kinase, has high selectivity and good safety, and is a potential therapeutic drug for RIPK1 kinase related diseases. TNF alpha induced SIRS model and mouse melanoma lung metastasis model experiments prove that the compound disclosed by the invention can play a role in inhibiting RIPK1 kinase in vivo and has remarkable anti-inflammatory and anti-tumor metastasis activity. The invention provides a new strategy and means for comprehensively treating tumor metastasis.
Owner:SICHUAN UNIV
Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf
InactiveUS20180369417A1Improve immunityImprove anti-cancer effectPeptide/protein ingredientsAntibody medical ingredientsAntitumor immunityWhite blood cell
The present invention relates to an oncolytic adenovirus simultaneously expressing interleukin-12 and shVEGF, and an antitumor immunity enhancing composition and an anticancer effect promoting composition each containing the same. The present inventors verified that the simultaneous occurrence of VEGF inhibition and IL-12 expression induced the recovery of an immune function and the promotion of an anticancer effect in an immunological mouse melanoma or kidney cancer model. Especially, the applicability of a gene carrier simultaneously expressing IL-2 and shVEGF in the cancer gene therapy was first established by disclosing that the increased anticancer effect is involved in an increase in anticancer immunity, an increase in TH 1 cytokine, and the prevention of tumor induced thymic atrophy.
Owner:GENEMEDICINE CO LTD
Genome edited cancer cell vaccines
PendingUS20200113986A1Reduce inhibitionIncrease immune recognitionGenetically modified cellsCulture processStage melanomaCytokine
A cancer vaccine technology is provided which knocks out expression of cell surface immune checkpoint proteins, to facilitate their processing by immune cells, and optionally by knocking-in the expression of cytokines to boost immune response. Non-replicating tumor cells lacking cell surface CD47 are highly effective immunizing agents against subcutaneous mouse melanoma. Whole-cell vaccines inhibited tumor growth, and immunophenotyping showed a dramatic increase in activated effector cell subsets and M1-type macrophages aided by a significant reduction in the tumor-associated macrophage and myeloid derived suppressor cell compartments. A remarkable downregulation of cell surface CD47 was observed in the tumors that did escape after vaccination with genetically modified cells, suggesting the intricate involvement of CD47 in a prophylactic situation. An effective vaccination strategy to increase tumor-specific immune response in solid tumors is provided to improve the outcome of cancer immunotherapy.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Preparation method and application of liver-restoring tablet
ActiveCN103599493ARich in active ingredientsReduce dosageDigestive systemPill deliveryActive ingredientLungs metastasis
The invention provides a preparation method for a liver-restoring tablet. The liver-restoring tablet is prepared from the bulk drugs consisting of 800 g of isatis root, 166 g of oriental wormwood, 266 g of curcuma tuber, 266 g of Chinese magnoliavine, 266 g of licorice, 133 g of Chinese angelica, 400 g of milk vetch and 200 g of acanthopanax root through supercritical extraction. With the preparation method, the content of the bulk drugs in the liver-restoring tablet is greatly increased, and the dose of the tablet is reduced. The invention further provides application of the liver-restoring tablet in preparation of drugs used for inhibiting cell proliferation of the mouse melanoma lung metastasis strain B16-F10.
Owner:海宁市钱塘新农村开发有限公司
Application and preparation method of Shuxinning tablets
InactiveCN103690751APrevent proliferationPill deliveryAntineoplastic agentsLigusticum chuanxiongAllium macrostemon
The invention provides an application of Shuxinning tablets in preparing a drug for suppressing the proliferation of murine B16 melanoma cells. A preparation method of the Shuxinning tablets comprises the following steps of: taking twelve medicinal raw materials including 100g of salvia miltiorrhiza, 100g of ligusticum wallichii, 200g of radix paeoniae rubra, 80g of safflower, 80g of angelica sinensis, 80g of radix pseudostellariae, 80g of allium macrostemon, 80g of trichosanthes peel, 60g of polygala tenuifolia, 60g of lignum dalbergiae odoriferae, 60g of rhizoma acori graminei and 60g of liquorice, and preparing the tablets by a conventional method.
Owner:QINGDAO CENT HOSPITAL
Preparation method for Torvosaurus liquid and application of Torvosaurus liquid
ActiveCN105193715AThe amount of medicinal materials increasedRich in active ingredientsAnthropod material medical ingredientsPharmaceutical delivery mechanismMicrowaveMelanoma
The invention provides a preparation method for Torvosaurus liquid. The Torvosaurus liquid is prepared by taking 25g of male silk moth, 25g of acanthopanax, 17.5g of wine-processed semen cuscutae, 20g of herba epimedii, 10g of salt-processed prepared rehmannia root and 10g of salt-processed fructus psoraleae as raw material medicines; the Torvosaurus liquid is prepared by microwave extraction, so that the Torvosaurus content is greatly increased, and the dose is reduced. The invention also provides the application of the Torvosaurus liquid in preparing drugs for restraining murine melanoma 16B cell proliferation and drugs for treating or preventing dengue virus infection.
Owner:云南云龙制药股份有限公司
Naphthaquinone compound derived from marine microbes, and preparation method and application thereof
InactiveCN104262130APrevent proliferationImprove anti-tumor activityOrganic chemistryMicroorganism based processesOsteogenic TumorSystematic name
The invention discloses a naphthaquinone compound derived from marine microbes, and a preparation method and application thereof. The systematic name of the compound is 1,2,3,4-tetrahydro-1,2,5-trihydroxy-6,7-dimethoxy-3-methyl-9,10-anthracenone, and the structure is disclosed as Formula (I). The naphthaquinone compound can be continuously obtained by fermentation. The compound has the advantages of high antineoplastic activity, environment friendliness and low use cost, and can be used for preparing antineoplastic drugs. The active naphthaquinone compound derived from microbes is small in amount and simple in structure, and can be used as a precursor of antineoplastic drugs; the structural modification and reconstruction on the basis of the prior art enhance the antineoplastic targeting property and efficiency; and when being used for developing drugs for treating human stomach cancer, human lung cancer, mouse melanoma, human mammary cancer, human pancreatic cancer, human cervical carcinoma, human osteogenic sarcoma, human liver cancer, human colon cancer and human laryngocarcinoma, the naphthaquinone compound has wide application prospects.
Owner:大丰海洋生物医药研究所 +3
Preparation method and application of breast lump dissipating tablet
InactiveCN103494915ARich in active ingredientsReduce dosagePill deliverySexual disorderTangerine FruitAdemetionine
The invention provides a preparation method of a breast lump dissipating tablet. The breast lump dissipating tablet is prepared from bulk drugs, including 825g of tangerine leaves, 825g of roots of red-rooted salvia, 550g of spina gleditsiae, 550g of seeds of cowherb, 550g of szechwan chinaberry fruit, and 550g of earthworms, through supercritical extraction, so that the content is improved greatly, and the dose is reduced. The invention also provides an application of the breast lump dissipating tablet in the preparation of medicines for inhibiting cell proliferation of mouse melanoma lung metastatic lines B16-F10.
Owner:侯俊光
(S,R)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
Owner:ONCONOX
Organotin-oxygen cluster containing ferrocene pyrazole and application of cluster
InactiveCN102093431BImprove biological activityLow toxicityTin organic compoundsAntineoplastic agentsDibutyltin oxideCoordination complex
The invention provides an organotin-oxygen cluster containing ferrocene pyrazole. The cluster is characterized in that the complexes with the following chemical formulas are prepared from a ligand 3-trifluoromethyl-5-ferrocene pyrazole acetic acid (LCOOH) and monobutyltin oxide, dibutyltin oxide and triphenyltin hydroxide respectively: [BuSnO(OOCL)]6, [Ph4Sn2O(OCH3)(OOCL)]2 and [Bu4Sn2O(OOCL)2]2.The cluster has inhibiting effects on human lung cancer cells (A549), hepatoma cells (HepG2) and mouse melanoma (B16-F10) and the inhibiting effects are obviously superior to the inhibiting effects of the control drugs 5-fluorouracil and cisplatin, so the cluster can be applied to preparing the anti-tumor drugs.
Owner:ANHUI UNIVERSITY
Preparation method and application of quercetin amide derivatives
InactiveCN103214445BStrong proliferation inhibitory effectOrganic active ingredientsOrganic chemistryHuman gastric carcinomaQuercitrin
The invention discloses a preparation method of a quercetin amide derivative and application of the quercetin amide derivative in preparing an antitumor drug. The preparation method of the quercetin amide derivative comprises the following steps of: carrying out benzyl selective protection, a Williamson ether forming reaction, a DCC (Dicyclohexylcarbodiimide) condensation reaction, catalytic hydrogenation and the line by using cheap rutin as the material. The preparation method of the quercetin amide derivative can be used for realizing the orientation and efficient modification of the quercetin, and is gentle in reaction conditions, simple to operate, simple in post-treatment and convenient for industrial production. The obtained quercetin amide derivative obviously has a stronger inbibitional effect to proliferation of a human esophageal squamous carcinoma cell EC (Ethyl Cellulose)109, a human esophageal squamous carcinoma cell EC9706, a human gastric carcinoma cell SGC (Soluble Guanylyl Cyclase) 7901 and a mouse melanoma cell B16-f10 relative to the quercetin, and therefore, the quercetin amide derivative is an anti-tumor candidate compound with great potential.
Owner:ZHENGZHOU UNIV
Use of TNFSF15 protein in preparation of melanoma treatment medicine
InactiveCN107537027AImprove stabilityHigh activityHeavy metal active ingredientsPeptide/protein ingredientsAbnormal tissue growthCisplatin
The invention relates to a use of a TNFSF15 protein in the preparation of a melanoma treatment medicine. It is found that the TNFSF15 can inhibit the growth of endothelial cells and induce the apoptosis of the endothelial cells, and also can inhibit the growth and migration of mouse melanoma cells B16 and induce the apoptosis of the mouse melanoma cells B16. When the TNFSF15 and a chemotherapeuticmedicine are simultaneously used to treat melanoma, the TNFSF15 can inhibit the generation of tumors by inhibiting the generation of tumor blood vessels, and also can enhance the killing effect of the chemotherapeutic medicine on melanoma cells by inducing melanoma cell apoptosis. The TNFSF15 can enhance the melanoma treatment effect of cisplatin when used in combination with the chemotherapeuticmedicine cisplatin which is commonly used to treat melanoma.
Owner:NANKAI UNIV
Preparation method of Qingmei cold tablet and application of Qingmei cold tablet in drugs for inhibiting melanoma cell B16 from cell proliferation
The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a preparation method and application of a Qingmei cold tablet. The preparation method comprises the following steps: by using 200g of southernwood, 267g of finger citron, 134g of elsholtzia, 200g of dicliptera, 134g of licorice, 134g of cat's-foot and 267g of holly root as active pharmaceutical ingredients, carrying out supercritical extraction and microwave extraction so that the glycyrrhizic acid content is greatly enhanced. The invention also provides application of the Qingmei cold tablet in preparing drugs for inhibiting mouse melanoma cell B16 from cell proliferation.
Owner:JINAN XINQIDIAN MEDICAL TECH
Usage of lactoferrin in prevention and treatment of tumor metastasis
ActiveCN102600459AGood curative effectRelieve side effectsPeptide/protein ingredientsAntineoplastic agentsLymphatic SpreadTherapeutic effect
The invention provides the usage of lactoferrin in prevention and treatment of tumor metastasis. Particularly, the invention provides the usage of the lactoferrin in preparation of a medicine for preventing or inhibiting tumor metastasis or tumor cell migration. The pharmacology experiment in the invention proves that the human lactoferrin has good prevention and treatment effects for the tumor metastasis, so that metastasis, colonization and growth of malignant tumors such as mouse melanoma and the like can be obviously inhibited.
Owner:SHANGHAI TRANSGENIC RES CENT
Fusion protein containing CD40 antibody and IL-15 and preparation method and application of fusion protein
ActiveCN113480662AImprove tumor targetingPromote secretionPeptide/protein ingredientsAntibody mimetics/scaffoldsTumor targetAntiendomysial antibodies
The invention discloses a bispecific fusion protein containing a cytokine IL-15 and a CD40 antibody or an immunocompetence fragment and a preparation method and application of the bispecific fusion protein. The fusion protein comprises the human CD40 antibody and the cytokine IL-15 with different structural formulas, and is obtained by co-transfection and expression of different plasmids. The fusion protein disclosed by the invention can activate APC cells, T cells and NK cells at the same time, and the tumor targeting property of the cytokine is enhanced; DC cell maturation and IL-12 secretion can be stimulated, the growth of mouse melanoma can be significantly inhibited, and the volume and average pulmonary metastasis of the melanoma can be reduced.
Owner:北京华奥玄德生物医药科技有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com